CADL Candel Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CADL

Price (delayed)

$9.02

Market cap

$264.71M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.31

Enterprise value

$251.8M

Highlights
The net income has dropped by 102% year-on-year and by 19% since the previous quarter
Candel Therapeutics's EPS has shrunk by 102% YoY and by 20% QoQ
Sector: Healthcare
Industry: Biotechnology
Peers: OMER OMGA

Key stats

What are the main financial stats of CADL
Market
Shares outstanding
29.35M
Market cap
$264.71M
Enterprise value
$251.8M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
20.47
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$35.34M
EBITDA
-$34.14M
Free cash flow
-$34.52M
Per share
EPS
-$1.31
Free cash flow per share
-$1.19
Book value per share
$0.44
Revenue per share
$0
TBVPS
$1.42
Balance sheet
Total assets
$41.2M
Total liabilities
$28.46M
Debt
$22.76M
Equity
$12.75M
Working capital
$22.61M
Liquidity
Debt to equity
1.79
Current ratio
2.59
Quick ratio
2.52
Net debt/EBITDA
0.38
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-69.9%
Return on equity
-142.9%
Return on invested capital
-177.2%
Return on capital employed
-130.8%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CADL stock price

How has the Candel Therapeutics stock price performed over time
Intraday
7%
1 week
41.16%
1 month
436.9%
1 year
467.3%
YTD
513.61%
QTD
470.89%

Financial performance

How have Candel Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$38.39M
Net income
-$37.94M
Gross margin
N/A
Net margin
N/A
The net income has dropped by 102% year-on-year and by 19% since the previous quarter
The company's operating income fell by 10% YoY and by 6% QoQ

Growth

What is Candel Therapeutics's growth rate over time

Valuation

What is Candel Therapeutics stock price valuation
P/E
N/A
P/B
20.47
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Candel Therapeutics's EPS has shrunk by 102% YoY and by 20% QoQ
Candel Therapeutics's equity has shrunk by 73% YoY and by 45% QoQ

Efficiency

How efficient is Candel Therapeutics business performance
The company's return on invested capital has shrunk by 150% YoY and by 33% QoQ
Candel Therapeutics's ROE has plunged by 58% from the previous quarter
CADL's ROA is down by 39% from the previous quarter

Dividends

What is CADL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CADL.

Financial health

How did Candel Therapeutics financials performed over time
The total assets is 45% greater than the total liabilities
CADL's quick ratio has dropped by 80% year-on-year and by 40% since the previous quarter
The current ratio has plunged by 80% YoY and by 41% from the previous quarter
Candel Therapeutics's debt is 79% higher than its equity
CADL's debt to equity has surged by 81% since the previous quarter
Candel Therapeutics's equity has shrunk by 73% YoY and by 45% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.